Ginkgo bioworks and centrient pharmaceuticals announce expansion of partnership following success of initial project to bring sustainable innovation to the generic api space

Rijswijk, netherlands and boston , may 25, 2023 /prnewswire/ -- centrient pharmaceuticals ("centrient"), the global business-to-business leader in sustainable antibiotics, next-generation statins and anti-fungals, and ginkgo bioworks (nyse: dna), which is building the leading platform for cell programming and biosecurity, today announced they are expanding their existing partnership aimed at broadening centrient's portfolio of environmentally friendly active pharmaceutical ingredients (apis), following the success of previous work together. ginkgo's ongoing partnership with centrient focuses on improving the sustainability of fermentation and enzymatic syntheses of beta-lactam antibiotic apis.
DNA Ratings Summary
DNA Quant Ranking